You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The company posted Q2 revenues of $13.1 million, down from $13.5 million in Q2 2019 but above the consensus Wall Street estimate of $11.8 million.
The firm delivered record revenue and the most profitable quarter in its history as a result of the increased demand for its products.
On an adjusted basis at constant exchange rates, revenues grew 19 percent year over year, in line with guidance provided by the company in early July.
The company reported $41.8 million in total revenues for the quarter and said testing services revenues rose 41 percent year over year.
Coastal Genomics owns the Ranger gel electrophoresis technology to collect specific DNA target sizes, with applications in noninvasive prenatal testing and oncology.
According to Snibe, the test has 99.6 specificity and 100 percent sensitivity at 15 days following the onset of symptoms for COVID-19.
Of the 28 companies in the index, 22 firms saw their stock prices increase, while six firms' share prices decreased.
Antelope is currently developing a urine-based at-home test for the sexually transmitted infections Chlamydia trachomatis and Neisseria gonorrhoeae.
Results from the Phase II INSPIRE study showed that change in ctDNA from baseline, as gauged by customized assays, predicted response to pembrolizumab.
Plummeting testing for routine care activities due to COVID-19 had a negative revenue impact in all regions during the third quarter, according to the firm's CFO.
The company recorded $111,000 in revenues from its recently launched SARS-CoV-2 antibody test, which runs on its MosiaQ blood testing platform.
Zeesan's test may be used by any CLIA-certified high-complexity lab, while UCSD's test, which uses pooled samples, must be performed by the university.
Both tests can detect SARS-CoV-2 in 90 minutes and will detect viruses like influenza and respiratory syncytial virus that tend to occur in the winter.
The Clarigene SARS-CoV-2 IVD kit uses two viral RNA targets, nucleocapsid gene N and envelope gene E, which are specific to COVID-19, the firm said.
The company believes the pandemic will accelerate the adoption of its cancer diagnostics as patients and doctors look for faster and more convenient tests.
The company recently had a second pre-submission with FDA and expects to begin a prospective trial of its test in the second half of this year.
Regular SARS-CoV-2 testing could limit COVID-19 cases on university campuses but results might vary based on the schools' behavioral interventions.
CEO Doug Bryant noted, in particular, what he expects will be a hunger for rapid protein-based antigen tests for the coronavirus that the market currently can't fill.
According to the company, the test has shown to be more sensitive and accurate than a COVID-19 anterior nasal swab test in the firm's EUA validation study.
The seven technologies feature different methods, including CRISPR and microfluidics, and can be performed in many settings and with a variety of sample types.